Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: An integrated analysis of zafirlukast trials

Thorax

Volumn 55, Issue 6, 2000, Pages 478-483

  Barnes, Neil C ^a   Miller, Christopher J ^b  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Leukotriene receptor antagonist; Zafirlukast

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PLACEBOS; TOSYL COMPOUNDS;

EID: 0034028670     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.6.478     Document Type: Article

References (29)

1. 1 Barnes NC. Efficacy and effectiveness in treatment of asthma. Eur Respir Rev 1995;30:284-7.
2. 2 Society of Pharmaceutical Medicine Expert Panel Report. Clinical development of drugs against asthma. J Pharm Med 1993;3:115-253.
3. 3 Kerrebijn KF, Van Essen-Zandvliet EEM, Neigens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on bronchial responsiveness in asthmatic children. J Allergy Clin Immunol 1987;79:653-9.
4. 2 agonist terbutaline with an inhaled steroid in newly detected asthma. N Engl J Med 1991;325:388-92.
5. 5 Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax 1993;48:817-23.
6. 6 Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group. J Allergy Clin Immunol 1994;94:676-83.
7. 7 Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
8. 8 Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
9. 9 Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204,219, a potent leukotriene D, receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
10. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
11. 4 receptor antagonist, in subjects with bronchial asthma. Accolate Asthma Trialists Group. Am J Respir Crit Care Med 1994;150:618-23.
12. 12 Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997;19: 675-90.
13. 13 Nathan RA, Bernstein JA, Bielory L, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate airflow obstruction. J Allergy Clin Immunol 1998;102:935-42.
14. 14 Nathan RA, Minkwitz MC, Bonuccelli CM. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Ann Allergy Asthma Immunol 1999;82:497-503.
15. 15 Holgate ST, Anderson KD, Rodgers EM. Comparison of 'Accolate' (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients (abstract). Allergy 1995; 50(Suppl 26):319-20.
16. 16 Global Initiative for Asthma. Pocket guide for asthma management and prevention. NIH Publication No. 96-3659B. Bethesda, MD: National Heart, Lung, and Blood Institute; 1995.
17. 17 National Heart, Lung, and Blood Institute. Executive summary: guidelines for the diagnosis and management of asthma. NIH Publication No. 91-3042A. Bethesda, MD: National Asthma Education Program, US Department of Health and Human Services, Public Health Service, 1991.
18. 18 Ayres JG, Barnes PJ, Bellamy D, et al. British guidelines on asthma management: 1995 review and position statement. Thorax 1997;52(Suppl 1):S1-21.
19. 19 Agresti A. Categorical data analysis. New York: John Wiley, 1990: 230-2.
20. 20 SAS/STAT User's Guide, Vol 1. 4th ed. Cary, NC: SAS Institute Inc, 1990: 876-7.
21. 21 Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6.
22. 22 Senn S. Statistical issues in drug development. Chichester, UK: John Wiley, 1997: 219-35.
23. 23 Israel E, Cohn J, Dubé LM, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. J Am Med Assoc 1996;275:931-6.
24. 24 Liu MC, Dubé LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98:859-71.
25. 25 Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213-20.
26. 26 Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann Intern Med 1999;130:487-95.
27. 27 Wilding P, Clark M, Coon JT, et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997;314:1441-6.
28. 28 Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998;11:1232-9.
29. 29 Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-80.